Table of Contents
Trial overview
The clinical trial data show one study that includes Lixisenatide as part of treatment for adults with type 2 diabetes.[1] The study is named SURPASS-EARLY and is an interventional trial, which means researchers are comparing treatment plans rather than just observing people.[1]
Study design and phase
This trial is a Phase 3 study.[1] Phase 3 trials are later-stage studies that test treatments in larger groups and compare how well they work.[1] The trial is authorised and includes 781 participants.[1]
Who can participate
The trial is designed for adult participants with type 2 diabetes.[1] The source data do not list more detailed entry rules, so the main target group is adults living with this condition.[1]
What is being measured
The main outcome is the change from baseline in Hemoglobin A1c (HbA1c).[1] HbA1c is a blood test that shows average blood sugar over time, so it helps researchers see how well treatment controls diabetes.[1] The brief summary says the study aims to show that tirzepatide is non-inferior to intensified conventional care for HbA1c change from baseline to Week 104.[1] Non-inferior means the treatment is not worse than the comparison by more than a set amount.[1]
Trial details
The trial compares tirzepatide with intensified conventional care, which means stronger standard diabetes treatment.[1] The intervention list also includes several other diabetes medicines and treatment options, such as semaglutide, dulaglutide, exenatide, liraglutide, sitagliptin, and Lixisenatide.[1] The data provided do not explain the exact role of each listed treatment arm, but they show that Lixisenatide is one of the treatments included in this comparison study.[1]
The study follows participants for 104 weeks, which is about 2 years.[1] This long follow-up helps researchers see how treatment effects change over time.[1]
In simple terms, this trial is trying to learn whether the study treatment plan can control blood sugar as well as, or better than, standard care in adults with type 2 diabetes.[1]
